CE Mark European Approval

Advanced Medical Solutions Grp PLC
08 February 2005


For Immediate Release                                          8 February, 2005


                      Advanced Medical Solutions Group plc

                            ('AMS' or 'the Company')
        Announces European regulatory approval and market introduction of
              advanced woundcare hydroalginate dressings with silver

Winsford, UK: Advanced Medical Solutions (AIM: AMS), the global woundcare
technology company, is pleased to announce that it has received CE mark approval
for a range of hydroalginate woundcare dressings with silver allowing them to be
sold throughout Europe.  The products will be marketed by Johnson & Johnson
Wound Management, a division of ETHICON, INC. under the brand SILVERCEL*
Hydroalginate Dressing with Silver.

SILVERCEL Hydroalginate Dressings combine the potent broad spectrum
antimicrobial action of silver with the absorption of alginate - a natural wound
dressing derived from seaweed.

On 27th June 2003, AMS announced that it had entered an exclusive supply
agreement with Johnson & Johnson Wound Management for a range of alginate
woundcare dressings containing silver, using X-STATIC(R) silver fibre technology
from Noble Fiber Technologies Inc.  The X-STATIC silver fibre technology
utilises a layer of pure silver bonded to the surface of a textile fibre, which
provides a reservoir for silver ion release for wounds requiring sustained
protection and therapy and which enables it to be incorporated into the alginate
dressing. AMS subsequently developed calcium alginate products, which allow a
controlled and sustained release of silver into the wound without compromising
the performance of the alginate as an advanced woundcare dressing.

On 8th July 2003, AMS announced that it had received 510(k) clearance by the
FDA, allowing sale of these products into the US.  It was subsequently announced
on 27th April 2004 that Johnson & Johnson Wound Management had introduced the
range into this market.

With the European approval and market introduction announced today, the products
are now widely available on a global basis.

Commenting on today's announcement, Dr. Don Evans, Chief Executive of AMS, said:

'I am delighted that this product will now be available in Europe as part of an
antimicrobial wound dressings platform.  With inventive products such as silver
alginate dressings, we are committed to advancing wound care technology for
chronic and acute wound management'.

'This launch is another key milestone for AMS in delivering our stated strategy
of launching novel woundcare products with major global players'.

For further information, please contact:

Advanced Medical Solutions Group plc                  Tel : [phone]
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com

Buchanan Communications                               Tel: [phone]
Mark Court, Mary-Jane Johnson

Notes to Editors:

Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is
focused on the design, development and manufacture of innovative and
technologically advanced products for woundcare and other medical applications.

In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.

The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives that offer benefits over sutures and
staples for closing wounds sold direct to hospitals or through distributors.

AMS's technology and products currently serve the majority of the key global
markets with strategic partners including 3M, Novartis, Johnson & Johnson,
Molnlycke Healthcare, Smith + Nephew and Cardinal Health.


                      This information is provided by RNS
            The company news service from the London Stock Exchange